FindTrial
Sign In

Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma - Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042502
Enrollment
50
Registered
2020-11-20
Start date
2019-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

None listed

Sponsors

Japan Red Cross Medical Center
Lead Sponsor
Shonan Kamakura Hospital the Jikei University Kashiwa Hospital Disaster Medical Center Shibukawa Medical Center Japan Red Cross Himeji Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Cases are diagnosed as multiple myeloma. Cases received 4 cycles or more of Elotuzumab, lenalidomide plus dexamethasone (ERd) from November 2016 to June 2018.

Exclusion criteria

Exclusion criteria: Cases received ERd as clinical trial.

Design outcomes

Primary

MeasureTime frame
overall response rate, very good partial response rate, complete response rate—

Secondary

MeasureTime frame
progression free survival overall survival time to nexuses treatment—

Countries

Japan

Contacts

Public ContactKenshi Suzuki

Japan Red Cross Medical Center Hematology

ken-suzuki@mtb.biglobe.ne.jp03-3400-1311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026